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Background: Angiotensin II type 1 receptor blockers (ARB) are a frequently used class of antihypertensive drug. The
ARB losartan is known to decrease the serum uric acid (SUA) level. However, there are very few clinical data comparing
the effects of other ARBs on SUA level under the conditions of clinical practice. This study evaluated and compared the
long-term effects of monotherapy with five ARBs on SUA level in Japanese hypertensive patients with type 2 diabetes
mellitus (DM).
Methods: We identified hypertensive patients with type 2 DM who had been treated with monotherapy with losartan
(n = 214), valsartan (n = 266), telmisartan (n = 185), candesartan (n = 458), or olmesartan (n = 192), in whom laboratory
data of SUA between November 1, 2004 and July 31, 2011 were available, from the Nihon University School of Medicine’s
Clinical Data Warehouse (NUSM’s CDW). We used a propensity-score weighting method and a multivariate regression
model to adjust for differences in the background among ARB users, and compared the SUA level. The mean exposure
of losartan was 264.7 days, valsartan 245.3 days, telmisartan 235.9 days, candesartan 248.9 days, and olmesartan
234.5 days.
Results: In losartan users, mean SUA level was significantly decreased from baseline, while it was conversely increased
in users of other ARBs; valsartan, telmisartan, candesartan, and olmesartan. The mean reduction of SUA level from
baseline was significantly greater in losartan users compared with that in other ARB users. Comparison of ARBs other
than losartan showed no significant difference in mean change in SUA level from baseline.
Conclusions: Our study showed that losartan had the most beneficial effect on SUA level among five ARBs, and that
there was no significant difference in the unfavorable effects on SUA level among four ARBs other than losartan, at
least during one year. These findings provide evidence of an effect of ARBs on SUA level, and support the benefit of
the use of losartan in hypertensive patients with type 2 DM.
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A high concentration of serum uric acid (SUA) is the
main cause of gout, and is also associated with the meta-
bolic syndrome, including hypertension and diabetes
mellitus (DM) [1-3]. In the report of the US National
Health and Nutrition Examination Survey, among pa-
tients with gout, 74% had hypertension and 26% had
diabetes [4]. Hypertension, DM, and hyperuricemia are
mutually related; therefore, regular monitoring of serum
uric acid levels is desirable in hypertensive patients
with DM [5].
Many patients with hyperuricemia are using antihyper-
tensive agents because hypertension and hyperuricemia
are conditions that frequently coexist. The effect of anti-
hypertensive agents on uric acid differs according to
their mechanism of action. Beta blockers and thiazide di-
uretics increase the SUA level whereas alpha-blockers
and calcium-channel blockers (CCB) decrease the SUA
level [6,7]. The effect of angiotensin II type I receptor
blockers (ARBs) on the SUA level differs among drugs.
Of ARBs, losartan decreases the SUA level [8-10] via its
influence on urate transporter 1 (URAT1) [11-13]. Dif-
fering from losartan, valsartan and candesartan have
been reported to increase the SUA level in patients with
hypertension [14,15].
Several studies have compared the effect of losartan
on SUA with that of another drug or placebo. However,
these studies were mainly randomized clinical trials
(RCTs) in which the efficacy of a treatment in optimal
controlled experimental conditions was evaluated, and
few studies have compared therapeutic effectiveness
using a clinical databases, under the conditions of clin-
ical practice. In addition, few studies have performed a
multiple comparison of the effects on SUA level among
various ARBs in clinical practice, and few studies have
compared the long-term effect of ARB monotherapies
on SUA in hypertensive patients with type 2 diabetes
mellitus. The aim of this study was to evaluate and com-
pare the long-term effect of five ARB monotherapies;
losartan, valsartan, candesartan, telmisartan, and olme-
sartan, on SUA in Japanese hypertensive patients with
type 2 diabetes mellitus, in a real-world setting.
Materials and methods
Data source
We used the Nihon University School of Medicine
(NUSM) Clinical Data Warehouse (CDW) for this retro-
spective database study. NUSM’s CDW is a centralized
data repository that integrates separate databases, in-
cluding an order entry database and a laboratory results
database, from the hospital information systems at three
hospitals affiliated to NUSM. The prescribing data of
over 0.5 million patients are linked longitudinally to de-
tailed clinical information such as patient demographics,diagnosis, and laboratory data. Several epidemiological
studies examining the effects of drugs on glucose and
lipid metabolism and renal function using NUSM’s
CDW have been published [16-18].
Study populations
We identified Japanese type 2 DM patients with mild to
moderate hypertension aged over 20 years, who had
been newly treated with ARB monotherapy for at least
two months between November 1, 2004 and July 31, 2011.
DM was diagnosed according to the Committee for the
Classification and Diagnosis of Diabetes Mellitus of the
Japan Diabetes Society (defined as fasting plasma glucose
level ≥126 mg/dl, casual plasma glucose level ≥200 mg/dl,
plasma glucose 2 h after 75 g glucose load ≥200 mg/dl, or
HbA1c (NGSP) level ≥6.5% [19]).
The five ARBs used in this study were losartan potas-
sium, valsartan, telmisartan, candesartan cilexetil, and
olmesartan medoxomil (Table 1). The number of hyper-
tensive type 2 DM patients treated with losartan was
3599, valsartan 6918, telmisartan 4091, candesartan
8730, and olmesartan 5746. We excluded patients who
had been treated with other antihypertensive drugs
(ARB combination drugs, angiotensin-converting en-
zyme inhibitor, CCB, diuretic, alpha-blocker, beta-
blocker, alpha and beta blocker, alpha-agonist, reserpine,
vasodilator, or renin inhibitor) during the study period.
We also excluded patients who had been treated with
drugs for hyperuricemia or insulin during the study
period. The numbers of monotherapy patients in this
study were; losartan (n = 214), valsartan (n = 266), telmi-
sartan (n = 185), candesartan (n = 458), and olmesartan
(n = 192) (Table 1). The experimental protocol was ap-
proved by the Ethical Committee of Nihon University
School of Medicine and was conducted in compliance
with the ethical guidelines for epidemiological research
of the Ministry of Education, Culture, Sports, Science
and Technology and the Ministry of Health, Labour and
Welfare Japan [20].
Exposure and measurements
The baseline measurement period (non-exposure period)
was defined as within 12 months before the start of ARB
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period) was defined as between 2 and 12 months after the
start of ARB monotherapy. Laboratory data of the level of
SUA for each subject were collected at the date nearest
the start of ARB monotherapy in the baseline period, and
at the date nearest 12 months after the start of ARB
monotherapy in the exposure period. The mean exposure
of losartan was 264.7 days, valsartan 245.3 days, telmisar-
tan 235.9 days, candesartan 248.9 days, and olmesartan
234.5 days.
Data elements
For each patient, we collected information of patient
demographics (age and sex), medical history, use of
medication, and laboratory results as baseline covariates
for adjustment. Medical history included cerebrovascular
disease (ICD-10 code; I60-69), ischemic heart disease
(I20-I25), other heart disease (I30-I52), malignant neo-
plasm (C00-C97), thyroid gland disorder (E00-E07),
rheumatoid disease (M5, M6), liver disease (K70-K77),
kidney disease (N00-N19), hyperlipidemia (E78.0-E78.5),
and proteinuria diagnosed in the 365 days preceding the
first date of prescription of ARB. Drugs used during the
60 days before the start of ARB monotherapy included
oral hypoglycemic drugs, immunosuppressive drugs, lipid-
lowering drugs (including statins, fibrates, and other
lipid-lowering drugs), thyroids drugs, antipsychotics, an-
tithrombotic drugs, chemotherapeutic drugs, liver disease
therapeutics, chronic kidney disease (CKD) therapeutics
drugs, steroids, non-steroidal anti-inflammatory drugs
(NSAIDs), proton pump inhibitors, and histamine H2
receptor blockers.
Statistical analysis
All statistical analyses were performed with SAS soft-
ware, version 9.2 (SAS Institute Inc., Cary, NC). This is
a retrospective observational study. Because the non-
randomized subjects had inherent issues of selection bias
and confounding factors, we used a propensity-score
method to minimize selection bias, and a multivariate
regression model to measure the effect of ARBs on SUA
while controlling for baseline confounders. To adjust for
differences in baseline covariates among ARB users, we
performed a propensity-score weighting technique [21-23].
This method is also known as the inverse probability of
treatment weighted (IPTW) estimator, described by Robins
and colleagues [24]. The details of the IPTW method are
described elsewhere [22,24]. In brief, the propensity score
was calculated using a logistic regression model that in-
cludes the predictor variable (ARBs) as an outcome and all
baseline covariates (including sex, age, medical history,
and previous drugs) as shown in Table 2. After the propen-
sity score was constructed, we calculated the ‘propensity
score weight’ as the inverse of the propensity score. Then,propensity score-weighted (IPTW-adjusted) analysis was
performed to balance the difference in baseline character-
istics among ARBs and minimize the selection bias. We
used IPTW-adjusted chi-squared test for categorical data,
and an IPTW-adjusted linear regression model with
Tukey’s post-hoc analysis for continuous variables to
compare the difference in baseline characteristics among
ARB users. We used multivariate regression models with
Dunnett-Hsu post-hoc analysis to compare the mean
values of SUA at baseline and during the exposure period
in users of each ARB. We used an IPTW-adjusted multi-
variate regression model with Tukey’s post-hoc analysis to
compare the mean change from the baseline value to the
exposure value among ARB users. The model was ad-
justed for age, sex, medical history and previous medica-
tion, as listed in Table 2. All reported p-values are two
sided. A result was considered statistically significant if the
p value was less than 0.05.Results
Tables 2 and 3 show the characteristics of the patients
who had been treated with ARB monotherapy, before
and after IPTW adjustment. Before adjustment, there
were significant differences among users of different
ARB in the mean values of age, frequency of men, preva-
lence of rheumatoid and kidney disease, and the frequency
of use of oral hypoglycemic drugs, immunosuppressive
drugs, antipsychotics, liver disease therapeutics, steroids,
NSAIDs, proton pump inhibitors, and H2 blockers
(Table 3). After adjustment, there was no statistically sig-
nificant difference in all covariates among the ARB users.
After adjustment, the mean age of losartan users was 63.4,
valsartan 62.7, telmisartan 63.4, candesartan 62.4, and
olmesartan 62.9 years. After adjustment, the frequency of
men was 60.0% in losartan users, 61.2% in valsartan users,
59.3% in telmisartan users, 60.9% in candesartan users,
and 55.8% in olmesartan users.
Table 4 shows the results of laboratory tests at baseline
and during the exposure period. In losartan users, the
mean level of SUA was significantly decreased in the ex-
posure period compared with the baseline level. In users
of other ARBs, valsartan, telmisartan candesartan, and
olmesartan, the mean levels of SUA were significantly
increased in the exposure period compared with those
in the baseline.
Table 5 shows the mean change in SUA level during
the exposure period from baseline, after IPTW adjust-
ment. The reduction of SUA level in losartan user was
significantly greater in comparison with that in valsartan,
telmisartan, candesartan, and olmesartan users. There
was no significant difference in the increase of SUA level
among the users of ARBs other than losartan; valsartan,
telmisartan, candesartan, and olmesartan.
Table 2 Baseline characteristics
Characteristics Number of the patients
Losartan Valsartan Telmisartan Candesartan Olmesartan
Total number of patients 214 266 185 458 192
Men 113 172 113 272 127
Medical History
Cerebrovascular disease 61 86 63 135 47
Ischemic heart disease 70 93 69 168 50
Other heart disease 54 75 43 118 49
Malignant neoplasm 104 136 87 252 105
Thyroid disease 76 78 67 149 69
Rheumatoid disease 56 33 35 68 19
Liver disease 111 148 99 265 104
Kidney disease 127 132 116 226 90
Hyperlipidemia 128 167 112 287 113
Proteinuria 96 98 71 170 73
Current Medication
Oral hypoglycemic drugs 46 78 62 129 69
Immnosupressive drugs 16 6 6 11 5
Lipid-lowering drugs 86 99 65 183 69
Statin 69 75 53 134 52
Fibrate 6 11 6 26 8
Other lipid-lowering drugs 21 18 13 42 13
Thyroid drugs 8 5 6 16 2
Antipsychotic drugs 22 11 6 23 7
Antithrombotic drugs 72 87 63 133 44
Chemotherapeutics drugs 3 9 4 21 4
Liver disease therapeutics 15 10 4 15 13
CKD therapeutic drugs 6 0 0 2 0
Steroids 40 23 24 49 13
NSAIDs 82 96 57 132 52
Proton pump inhibitors 47 34 35 73 35
H2 blockers 48 38 26 75 23
NSAID, Non-steroidal anti-inflammatory drug; CKD, Chronic kidney disease.
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In this study, we evaluated and compared the effect of
long-term monotherapy, up to one year, among five
ARBs on SUA in hypertensive patients with type 2 DM.
The mean level of SUA after treatment with losartan
significantly decreased compared with the baseline. The
mean level of SUA after treatment with other ARBs (val-
sartan, telmisartan, candesartan, and olmesartan) signifi-
cantly increased compared with baseline. The reduction
of SUA level from baseline in losartan users was signifi-
cantly greater than that in other ARB users. This study
suggests that, among the five ARBs, losartan had the
most beneficial effect on SUA in hypertensive patients
with type 2 diabetes mellitus.It is known that losartan decreases the level of SUA in
clinical practice and in animals. In clinical practice, some
studies have reported a lowering effect of losartan on
SUA level. It was reported that losartan significantly
lowered SUA compared to placebo in patients with type
2 diabetes and nephropathy [9]. In patients with hyper-
tension, 12-week treatment with losartan decreased the
mean level of SUA compared with baseline [14]. In pa-
tients with mild to moderate hypertension, the mean
level of SUA was significantly decreased from baseline
after 12 weeks of treatment with losartan [25]. A study
using xenopus oocytes, an in vitro study, and adminis-
tration in hypertensive patients have revealed that losar-
tan decreases SUA level via inhibition of URAT 1, which
Table 3 Baseline characteristics before and after IPTW adjustment (percent distributions)
Characteristics †Percent distribution
Before adjustment After IPTW adjustment
Losartan Valsartan Telmisartan Candesartan Olmesartan p value Losartan Valsartan Telmisartan Candesartan Olmesartan p value
Age (years, mean ± SE) 60.1 ± 0.8 63.4 ± 0.8 63.2 ± 0.9 63.2 ± 0.6 61.2 ± 0.9 0.0084* 63.4 ± 0.8 62.7 ± 0.8 63.4 ± 0.9 62.4 ± 0.6 62.9 ± 0.9 0.8485
Men 52.8 64.7 61.1 59.4 66.2 0.0394* 60.0 61.2 59.3 60.9 55.8 0.7809
Medical History
Cerebrovascular disease 28.5 32.3 34.1 29.5 24.5 0.2667 28.5 31.0 32.5 29.3 30.1 0.9066
Ischemic heart disease 32.7 35.0 37.3 36.7 26.0 0.0917 30.1 34.0 35.4 34.7 30.8 0.6735
Other heart disease 25.2 28.2 23.2 25.8 25.5 0.8313 26.7 26.3 25.1 25.7 23.3 0.9434
Malignant neoplasm 48.6 51.1 47.0 55.0 54.7 0.2735 52.0 52.0 52.6 52.4 52.1 0.9999
Thyroid disease 35.5 29.3 36.2 32.5 35.9 0.4354 31.6 32.0 34.0 33.8 35.0 0.9302
Rheumatoid disease 26.2 12.4 18.9 14.9 9.9 <.0001* 17.5 14.5 15.8 16.4 16.0 0.9361
Liver disease 51.9 55.6 53.5 57.9 54.2 0.6296 52.8 55.3 57.0 54.5 53.5 0.9303
Kidney disease 59.4 49.6 62.7 49.3 46.9 0.002* 47.7 52.1 54.3 52.6 51.8 0.7232
Hyoerlipidemia 59.8 62.8 60.5 62.7 58.9 0.8559 58.3 61.0 61.1 60.7 61.8 0.9594
Proteinuria 44.9 36.8 38.4 37.1 38.0 0.3621 38.5 37.5 35.5 38.5 41.8 0.7941
Current Medication
Oral hypoglycemic drugs 21.5 29.3 33.5 28.2 35.9 0.0155* 31.0 30.7 28.8 28.6 29.9 0.9614
Immunosuppressive drugs 7.5 2.3 3.2 2.4 2.6 0.0077* 3.7 2.6 3.7 3.1 2.7 0.9372
Lipid-lowering drugs 40.2 37.2 35.1 40.0 35.9 0.6958 35.1 39.0 39.0 39.0 38.1 0.8877
Statin 32.2 28.2 28.7 29.3 27.1 0.8211 27.3 30.2 29.6 29.5 28.6 0.9659
Fibrate 2.8 4.1 3.2 5.7 4.2 0.4381 3.1 4.2 4.8 4.5 4.8 0.8962
Other lipid-lowering drugs 9.8 6.8 7.0 9.2 6.8 0.5729 8.3 8.9 9.2 8.2 7.0 0.9402
Thyroid drugs 3.7 1.9 3.2 3.5 1.0 0.3284 2.6 2.2 2.7 3.1 2.7 0.971
Antipsychotic drugs 10.3 4.1 3.2 5.0 3.7 0.007* 5.7 3.8 4.1 4.6 7.2 0.5156
Antithrombotic drugs 33.6 32.7 34.1 29.0 22.9 0.0783 27.7 30.7 30.6 30.0 29.6 0.9579
Chemotherapeutic drugs 1.4 3.4 2.2 4.6 2.1 0.1554 3.1 3.1 4.9 3.3 3.1 0.8304
Liver disease therapeutics 7.0 3.8 2.2 3.3 6.8 0.0405* 4.4 4.2 3.0 3.8 5.4 0.834
CKD therapeutic drugs 2.8 0.0 0.0 0.4 0.0 0.0003* 0.6 0.0 0.0 0.9 0.0 0.236
Steroids 18.7 8.7 13.0 10.7 6.8 0.0012* 9.7 10.1 11.4 10.6 10.7 0.9859
NSAIDs 38.3 36.1 30.8 28.8 27.1 0.0347* 29.8 32.1 32.7 31.2 31.1 0.9771
Proton pump inhibitors 22.0 12.8 18.9 15.9 18.2 0.087* 18.1 17.5 16.2 16.9 19.6 0.9208
H2 blockers 22.4 14.3 14.1 16.4 12.0 0.0395* 14.9 15.6 19.1 15.9 18.4 0.7162
IPTW, Inverse probability of treatment weighted; SE, Standard error; NSAID, Non-steroidal anti-inflammatory drug; CKD: Chronic kidney disease. *: p < 0.05 (chi-squared test for categorical data, linear regression model

















Table 4 Adjusted mean level of SUA at baseline and during
exposure period
ARB Baseline Exposure p value
Mean 95% CI Mean 95% CI
Losartan 5.18 (5.03, 5.32) 5.04 (4.90, 5.19) 0.0194*
Valsartan 5.30 (5.15, 5.45) 5.49 (5.34, 5.63) 0.0012*
Telmisartan 5.34 (5.18, 5.49) 5.47 (5.32, 5.63) 0.0253*
Candesartan 5.54 (5.43, 5.65) 5.68 (5.57, 5.79) 0.0011*
Olmesartan 5.39 (5.22, 5.56) 5.58 (5.41, 5.75) 0.0013*
ARB, Angiotensin II type I receptor blocker; CI, Confidence interval. *: p < 0.05
(exposure period vs baseline, Dunnett-Hsu post-hoc analysis). Analyses were ad-
justed for covariates including age, sex, medical history and previous medication.
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imal renal tubule [11-13]. Supporting these previous
reports, our study indicated that long-term monotherapy
with losartan has a beneficial effect on SUA level in
mildly to moderately hypertensive patients with type 2
DM. Because hypertension, DM and hyperuricemia often
coexist, therapy with losartan is suitable for hypertensive
patients with type 2 DM.
In a comparison of ARBs, it has been shown that the
reduction of SUA level by losartan is stronger than that
by other ARBs. In patients with hypertension and serum
uric acid ≥ 7 mg/dL, the mean level of SUA was signifi-
cantly decreased after 24 weeks of losartan treatment
compared with candesartan treatment [15]. In one study,
losartan but not irbesartan significantly lowered SUA
level compared to placebo in patients with type 2 dia-
betes and nephropathy [8]. The risk of onset of gout,
which is strongly related to SUV level, has been reported
to be lower in losartan users than in other ARB or CCB
users [25,26]. In this multiple comparison study, we
showed that losartan had the most beneficial effect on
SUA level among five ARBs in hypertensive patients
with type 2 DM. Based on these clinical findings, losar-
tan should be preferentially used in patients with hyper-
tension, especially in those with comorbid disease of
hyperuricemia or gout, over other ARBs.
Some in vitro studies have investigated the different
effects of ARBs on URAT1, which may explain the variable
effects of ARBs on SUA level. Candesartan, olmesartanTable 5 Adjusted mean change of SUA level from baseline to
ARB Mean 95% CI
vs Losartan
ΔLosartan −0.124 (−0.243, −0.0055) -
ΔValsartan 0.186 (0.0824, 0.289) 0.0012*
ΔTelmisartan 0.150 (0.0239, 0.275) 0.0172*
ΔCandesartan 0.153 (0.0755, 0.231) 0.0013*
ΔOlmesartan 0.166 (0.0413, 0.290) 0.0089*
ARB, Angiotensin II type I receptor blocker; CI, Confidence interval. Δ: mean change
ARBs, Tukey’s post-hoc analysis). Analyses were adjusted for covariates including agand valsartan did not show a cis-inhibitory effect but
showed a trans-stimulatory effect on URAT1, potentially
leading to an increase of SUA level [12]. Corresponding
with these in vitro studies, several clinical studies have
reported that some ARBs increased SUA level. In patients
with hypertension, 12-week treatment with valsartan in-
creased the mean level of SUA compared with baseline
[14]. In patients with coronary artery disease, the mean
SUA level in valsartan users was increased compared with
the baseline [27]. In patients with mild to moderate hyper-
tension, the mean level of SUA was significantly increased
after 12 weeks of treatment with candesartan [25]. In this
study, the mean SUA level in candesartan, olmesartan and
valsartan users was increased in comparison with baseline,
and there was no significant difference in the mean change
of SUA level in the exposure period from baseline among
these ARBs. On the other hand, in the study using
xenopus oocytes, losartan and telmisartan exhibited a cis-
inhibitory effect on uric acid transport via URTA1, which
means a reduction of reabsorption of uric acid [12]. To
our knowledge, however, there is no clinical report that
telmisartan may decrease SUA level, whereas some clinical
studies have shown a lowering effect of losartan on SUA
level. In patients with hypertension, high-dose treatment
with telmisartan for three months significantly increased
SUA level [28]. In this study, we showed that long-term
monotherapy with telmisartan increased SUA level. The
reason for this discrepancy between in vitro and clinical
study outcomes is unclear. The contribution of other
mechanisms, e.g., disturbance of urinary excretion, which
may be predominant over the inhibitory effect on URTA1
in telmisartan users, cannot be excluded. Concerning
ARBs other than losartan, our findings suggest that regular
checks of SUA level are recommended in patients treated
with candesartan, olmesartan, valsartan or telmisartan.
Our study has several limitations. First, the retrospect-
ive and non-randomized nature of the design entailed
inherent issues of selection bias and confounding. We
used rigorous statistical methods to control potential
confounding variables between ARB users, including
IPTW adjustment and a multivariate regression model.
However, their ability to control for differences wasexposure period
p value






in SUA level during exposure period from baseline. *: p < 0.05 (p value among
e, sex, medical history and previous medication.
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An important potential confounding factor that could
affect the results of this study is renal function status.
This analysis was adjusted for covariates including kid-
ney disease, proteinuria and medication for CKD. How-
ever, other biochemical tests such as serum creatinine
and urea nitrogen were not estimated in this analysis be-
cause there were some missing data in the study popula-
tion. Other potential confounding factors that could not
be considered in this database study are alcohol intake,
smoking, body mass index (BMI) and muscle mass index
(MMI). Furthermore, the possibility that the findings of
comparison of the baseline and exposure period in each
treatment group may be confounded by other variables
should be considered when interpreting the results.
Therefore, the findings of our study, based on a non-
randomized design, call for further studies, such as similar
analyses of larger databases, prospective population-based
studies, and randomized clinical trials, for confirmation.
Second, we did not fix the daily dosage of ARBs, because
the achievement of BP goal requires various doses of an
agent across different individuals or even in the same indi-
vidual in clinical practice. This study was not designed to
assess the effects of ARBs at each dosage, because it is dif-
ficult to determine whether or not pharmacodynamics are
dose-dependent in clinical settings. However, we consider
that the findings of our study, using a sophisticated statis-
tical method in a real-world setting, are reliable and will
be informative for clinicians.Conclusion
The results of the present study suggested that losartan
had the most beneficial effect on SUA level among five
ARBs; losartan, valsartan, candesartan, telmisartan, and
olmesartan, at least up to one year. Our study provides
evidence of the long-term effect of various ARBs on
SUA level in hypertensive patients with type 2 DM.
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